255898-86-3

Upstream product

• 17356-08-0 thiourea 
• 359828-74-3 ethyl 4-(2,6-difluorophenyl)-2,4-dimethyl-3-oxobutanoate 
• 359828-68-5 (2RS)-2-(2,6-difluorophenyl)propanoic acid 
• 85068-28-6 2,6-difluorophenylacetic acid 

Downstream Products

• 1114507-71-9 6-[(1R)-1-(2,6-difluorophenyl)ethyl]-2-[(1S,2S)-2-(4-methoxyphenyl)cyclopropylmethylsulfanyl]-5-methyl-3H-pyrimidin-4-one 
• 1114507-68-4 6-[(1S)-1-(2,6-difluorophenyl)ethyl]-2-[(1S,2S)-2-(4-methoxyphenyl)cyclopropylmethylsulfanyl]-5-methyl-3H-pyrimidin-4-one 
• 1114507-62-8 6-[(1R)-1-(2,6-difluorophenyl)ethyl]-2-[(1R,2R)-2-(4-methoxyphenyl)cyclopropylmethylsulfanyl]-5-methyl-3H-pyrimidin-4-one 
• 1114507-65-1 6-[(1S)-1-(2,6-difluorophenyl)ethyl]-2-[(1R,2R)-2-(4-methoxyphenyl)cyclopropylmethylsulfanyl]-5-methyl-3H-pyrimidin-4-one 
• 1190928-75-6 C₁₆H₁₄F₂N₂OS 
• 1190928-76-7 C₁₆H₁₄F₂N₂OS 
• 1190928-77-8 C₂₃H₂₀F₂N₂O₂S 

Relevant academic research and scientific papers

6-[1-(2,6-Difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase

Two 2,6-difluoro-DABO derivatives (MC 1047, 1, and MC 1220, 2, respectively) were tested against endogenous, nontelomeric reverse transcriptase (endo-RT) in human differentiating cell systems to investigate their antiproliferative and cytodifferentiating

Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family

Preventing HIV transmission by the use of a vaginal microbicide is a topic of considerable interest in the fight against AIDS. Both a potent anti-HIV agent and an efficient formulation are required to develop a successful microbicide. In this regard, molecules able to inhibit the HIV replication before the integration of the viral DNA into the genetic material of the host cells, such as entry inhibitors or reverse transcriptase inhibitors (RTIs), are ideal candidates for prevention purpose. Among RTIs, S- and N-dihydroalkyloxybenzyloxopyrimidines (S-DABOs and N-DABOs) are interesting compounds active at nanomolar concentration against wild type of RT and with a very interesting activity against RT mutations. Herein, novel N-DABOs were synthesized and tested as anti-HIV agents. Furthermore, their mode of binding was studied by molecular modeling. At the same time, a vaginal microbicide gel formulation was developed and tested for one of the most promising candidates.

Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3 H)-ones: Effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes

A comparison of the effects of the 6-(2-chloro-6-fluorobenzyl)-2- (alkylthio)pyrimidin-4(3H)-ones (2-Cl-6-F-S-DABOs) 7-12 and the related 6-(2,6-difluorobenzyl) counterparts 13-15 in HIV-1 infected cells and in the HIV-1 reverse transcriptase (RT) assays

Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: Synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants

A series of novel S-DABO analogues, characterized by different substitution patterns at positions 2, 5, and 6 of the heterocyclic ring, were synthesized in a straightforward fashion by means of parallel synthesis and evaluated as inhibitors of human immun

Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4 (3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase

5-Alkyl-2-(alkylthio)-6-(2,6-difluorobenzyl)-3,4-dihydropyrimidin-4(3H)-ones (S-DABOs 2) have been recently described as a new class of human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) active at nan